.png)
.png)
Programme
Day 1 - Welcome
- 10 mins
Speaker:
Peter Coleman FCMA, MBA
Peter joined Roslin in March 2022, prior to that he was the CEO of Cobra Biologics a position he held from 2011 to Mar 2021 up to when the business was sold. He has over 20 years of ATMP CDMO experience as both CFO and CEO and he is a qualified accountant with an MBA from Manchester Business School. He joined Cobra as the CFO on its IPO in 2002, overseeing multiple acquisitions and fundraising activities. During his tenure as CEO of Cobra, he oversaw a rapid growth in both revenue and EBITDA as the business focussed on Advanced Therapies. He is an active member of the UK life science infrastructure as an MMIP representative. He is also a multiple award winner, with the Queen’s Award for Enterprise in 2018 and joint winner of the BIA Richard Wilson Impact Award in 2020 for his involvement in the BIA’s UK COVID Vaccine Taskforce.
Chair:
Steve Bates FMed Sci, OBE
Steve Bates has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
UK Strategy update
- 10 mins
Speaker:
Steve Bates FMed Sci, OBE
Steve Bates has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
UK Biomanufacturing Perspective
- 10 mins
A snapshot of the UK’s biomanufacturing landscape.
Speaker:
Dr Kit Erlebach
Kit is Strategic and Transformational Venture Manager at Fujifilm Diosynth Biotechnologies where he previously worked as a Biochemical Engineer until Lean Six Sigma was introduced in the business and he moved into R&D continuous improvement. The adaptation of some of the tools to the lab environment was essential and subsequent Black Belt qualification has shown that R&D departments can embrace LSS. Kit has subsequently applied LSS to quality and engineering. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. Kit has also worked in a volunteer sector where he managed a church for two years.
MaruX™: Redefining Biomanufacturing in the UK Through Novel Continuous Processing
- 60 mins
Continuous biomanufacturing provides a solution for uncertainty in capacity as drug candidates progress through clinical development to commercial supply. We present a case study describing the production of a monoclonal antibody using a novel single-use technology platform, 500 L scale process in a non-GMP pilot facility, which is a forerunner to secured investment and design of a continuous GMP manufacturing facility currently under construction in the UK.
Chair:
Lucy Foley, Chief Technology Officer, eXmoor pharma concepts
Speaker:
Jonathan Haigh
Jonathan Haigh has been active in the biopharmaceutical industry for over fifteen years working in both the bioprocess technology vendor and end-user sectors, holding positions in both the US and UK. He completed a Ph.D. in antibody purification from the University of Cambridge, and an MBA from Durham University Business School. Jonathan has fulfilled a number of technical, management and leadership roles encompassing biopharmaceutical innovation, process development, early-phase GMP operations, and novel technology evaluation to support merge & acquisitions. Having previously worked in Pall Corporation, he is currently Vice President, Process Development at FUJIFILM Diosynth Biotechnologies, leading a team of over 350 process development scientists and engineers across Mammalian, Microbial and Advanced Therapy technology platforms, and drives a number of technology and strategy development programmes towards advancing biomanufacturing. He has a number of patents and publications pertinent to the bioprocessing field.
New frontiers in medicines
- 75 mins
Chair:
Andy Jones, Medicines Manufacturing Challenge Director, Innovate UK
UK mRNA capabilities
Speaker:
Brendan Fish
Brendan is Director of New Product Introduction and Process Technology at GSK’s Barnard Castle Manufacturing Facility. He has technical accountability for introduction of all new products to site as well as managing the technical support and continuous improvement of existing products. Brendan joined GSK in October 2009 and was previously Director of Bioprocess Sciences at MedImmune Cambridge. In this role he was responsible for all aspects of the development of purification methodologies, product characterisation, QC, potency, formulation & drug delivery for MedImmune products in relation to their use in commercial pharmaceutical processes.
Transformative Exosome Therapeutics
Speaker:
Peter Jones, Vice President CMC, Evox Therapeutics
Richard Wilson Impact Award
- 15 mins
Presented by:
Dr Kit Erlebach
Kit is Strategic and Transformational Venture Manager at Fujifilm Diosynth Biotechnologies where he previously worked as a Biochemical Engineer until Lean Six Sigma was introduced in the business and he moved into R&D continuous improvement. The adaptation of some of the tools to the lab environment was essential and subsequent Black Belt qualification has shown that R&D departments can embrace LSS. Kit has subsequently applied LSS to quality and engineering. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. Kit has also worked in a volunteer sector where he managed a church for two years.
Awarded to:
ATAC
Kidney disease - a view of today's reality and the progress towards novel therapies. A snapshot of the difference we can make to patients.
- 75 mins
This session will explore how the progress in research and technology impacts the lives of patients living with kidney disease. In a presentation and panel format, we will gain a unique perspective with inputs from experts in clinical medicine, product development and patient advocacy. Come along and see how what you do changes lives
Chair:
Sharon Grimster
Sharon is a consultant at Redownes Ltd, having previously held leadership roles at Avacta, VaxEquity, ReNeuron, F-Star, Antisoma and Celltech. During her career she has had responsibility for a range of development functions, including CMC, project management, medical devices, regulatory affairs, preclinical, business operations and quality. Sharon is the Vice Chair of the Manufacturing Advisory Committee for the BIA, and was the 2019 winner of the Peter Dunnill award.
Title TBC
Speaker:
Sandra Currie
Sandra joined Kidney Research as Chief Executive in 2012 and her career in the voluntary sector spans almost 32 years to date. Her first career was in mental health nursing, and she was ward sister in a secure Mental Health Unit in Glasgow, her home city. Her work in the voluntary sector includes many years spent developing a fundraising career, including work for a major cancer charity, latterly as a Director of Fundraising. She has also served on various sector wide advisory boards and was a Trustee of the Motor Neurone Disease Association (MNDA). She has led the growth and development of the charity for ten years now and has overseen a significant increase in research spend and greater collaborative working across the renal community. Sandra enjoys the challenges of working in a charity that needs to widen its influence and significantly increase income, enabling more research and innovation to improve the prospects for kidney patients. She is a keen advocate of reducing both inequality and inequity, particularly in the health and social care setting, and advancing progress in public health.
A Journey Without Cure - New strategies on the Horizon
Speaker:
Dr Aoife Waters, Consultant Paediatric Nephrologist, Great Ormond Street Hospital
Building A Gene Therapy Platform to Address Chronic Kidney Diseases
Speaker:
Julian Hanak
Julian has worked in the biotechnology and biopharmaceutical sector for more than 25 years, holding senior leadership positions in small biotech, CDMO and large pharma companies. Graduating as a Biochemist from University College London he completed his Master’s at Bangor University before working in research at the Nation Institute for Medical Research (MRC), Bioproducts Laboratories and Astra Zeneca. He gained extensive Gene Therapy drug development, manufacturing and business development experience at Cobra Biologics, NightStar Therapeutics and Biogen, where he was SVP and the global head of Gene Therapy Product and Process Development. He is currently the Chief Development Officer at Purespring Therapeutics Ltd and is an honorary lecturer for UCL Biochemical Engineering.
Biotech Funding
- 75 mins
Chair:
Martin Turner
Martin is responsible for the BIA's policy outputs and public affairs activities, and leads on finance and tax policy and the BIA’s engagement with the investment community. He also provides the secretariat for the BIA’s Finance and Tax Advisory Committee. Martin has over ten years’ experience in policy and public affairs and has worked at the Royal Society, the Campaign for Science and Engineering, and the Association of Medical Research Charities. Before embarking on a career in policy, Martin completed a PhD in molecular biology at the University of Sheffield, where he also co-founded and was director of an award-winning science communication charity called Science Brainwaves. He has a BSc in molecular biology from the University of Manchester.
Panel Members:
Sarah Goulding
Sarah Goulding is one of the Challenge Directors within UKRI for the Medicines Manufacturing challenge. Sarah was previously Head of Relationship Management and a specialist in medicines manufacturing at the Knowledge Transfer Network (KTN) with 15 years of experience working with industry, academia and policy makers in cell and gene therapies, biologics and medicines manufacturing. Throughout her career to date, she has driven the formation of initiatives to enable collaboration and commercialisation that work across business, academia and policy makers in government and associated bodies such as bioProcessUK, the BioIndustry Association’s Cell and Gene Therapy Advisory Committee and the Medicines Manufacturing Industry Partnership. Sarah has also been Acting Director at the BioIndustry Association Scotland, and has a PhD in developmental biology.
Peter Dunhill Award Presentation and lecture
- 45 mins
Presented by:
Dr Stephen Ward
Stephen has held the position of CMO of the Cell and Gene Therapy Catapult since 2018, leading the strategic manufacturing, supply chain, skills and industrial growth programmes, and was CGT Catapult’s founding COO. As CMO, Stephen has led on the design, build and GMP licensing of the Stevenage CGT Catapult facility, making the facility central to the development of the largest cell and gene therapy cluster outside the US. He also leads set-up of the new CGT Catapult site in Braintree, which supports the national COVID-19 vaccine portfolio, plus the development of large scale manufacturing of cell and gene therapies. Stephen also works closely with industry stakeholders to develop and deliver impactful and first-of-their-kind national skill programmes, such as the Advanced Therapy Skills Training Network (ATSTN) and the Advanced Therapies Apprenticeship Community (ATAC). He brings to the organisation almost two decades of specialised cell and gene therapy expertise from his career in biological medicine research, development, and manufacturing. Stephen thrives on bringing cutting edge technologies to patients by developing commercially viable products and is passionate about expanding the UK’s cell and gene therapy manufacturing and development supply chain. He is a current member of the Medicines Manufacturing Industry Partnership leadership team, actively promoting and supporting biomanufacturing in Government as well as at a grass-roots level.
Reflections on a Career in Biotechnology - Success Based on Opportunism, Networking and Good Fortune!!
Awarded to:
Dr Peter R. Levison
Peter Levison has a career spanning over 30 years within the Biotechnology Industry. His background is Process Chromatography and spent many years within various R&D leadership roles responsible for the development and technical support of chromatography resins and membranes as well as columns and related chromatography hardware at both Whatman International and Pall Corporation. During the latter stages of his career, Peter moved into a Marketing Leadership role initially leading the Product Management team for Downstream Processing and introducing an end-to-end scalable Continuous Bioprocessing platform. Finally, he was responsible for developing strategic partnerships and collaborations within the Biotech community through the management of a network of Global Thought Leaders and collaborative partners by working with key industrialists and academics around the world, Peter retired in May 2022 and now spends time enjoying life and having the ability to do the activities that full-time work impedes. Peter has always been an advocate of networking and mentoring and continues to maintain relationships with the academic community, the research councils and the BIA to support the development of early career researchers. Peter holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Dept. of Biochemistry, University of Manchester. He has an MBA awarded through the Open University Business School, Milton Keynes, UK
Day 1 - Close
- 30 mins
Speaker:
Steve Bates FMed Sci, OBE
Steve Bates has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
MMIP overview - strategy and progress update
- 30 mins
An overview will be given of the ongoing Medicines Manufacturing Industry Partnership (MMIP) initiatives, including high level updates on each of the MMIP workstreams.
Speaker:
Brian Henry, Chair of MMIP and Vice President Drug Product Design, Pfizer
Dragon's Den - Sustainable Biotechnologies
- 90 mins
The potential of biotechnology goes far beyond healthcare, with new innovations in food, plastics, fuels. This session will hear from companies helping to deliver a more sustainable future using synthetic biology and sustainable biotechnology.
Chair:
Will Milligan
Will is Founder and CEO of Extracellular. Will is a bioprocess specialist focusing on advancing cellular agriculture as a sustainable, ethical alternative to traditional agriculture. Will has 10 years of experience in stem cell and gene therapy process development and scale-up, having formerly led Upstream Development at eXmoor Pharma. Will has an engineering doctorate in Biopharmaceutical Process Development and a master’s degree in Mechanical Engineering. Will also chairs the BIA LeaP Alumni group.
Title TBC
Speaker:
Simon Saxby
Simon is CEO of Leaf Systems International Ltd and advisor to the Board of CamCon Medical Ltd. He served as Visiting Lecturer in Industrial Biotechnology, Vienna Medical and Technical University, Advisor at The Boston University School of Management, USA, and is a lecturer for the Cambridge University Masters in Biotechnology Enterprise (MBE) programme. His international career in life sciences spans 40 years, beginning with two years at LMB Cambridge in the Clinical Oncology and Radiotherapeutics Unit, before moving into biotech in Cambridge with Coralab Research / Murex Diagnostics. Simon’s personal experience ranges from Research Scientist, technical sales, sales and marketing director, business division director and chief executive officer. He has been a founder and held senior management positions in biotech companies, including board director roles, since 1987. He has led the design, build and operation of GMP biologics manufacturing facilities in the UK, United States and Malaysia, including his role as Project Director for the design and build of the Cell and Gene Therapy Catapult Manufacturing Centre in Stevenage. Simon has been CEO of both private and public companies, and have led both the sale and acquisition of biotech companies. He believes his experience would enable him to add significant value to the continued growth of the UK PLC life sciences industry and would welcome the opportunity to make that contribution through membership of the BIA Board.
Reimagining scalable bioprocessing; a breakthrough in adherent cell culture
At CellRev, we don't believe in the mantra of build bigger or build more; we believe you can build better. Incumbent batch technologies occupy a larger footprint, use more valuable resources, and cost more to operate than a continuous industrial process at scale. CellRev will introduce their industry first continuous adherent cell cultivation technology and its ability to scale an entirely new sustainable food system and advancing cell therapy treatments.
Speaker:
Che Connon, CellRev
Title TBC
Speaker:
Jacqui Matthews, CSO, Roslin Technologies
Title TBC
Speaker:
Joel Eichmann
Joel Eichmann is a life scientist with a background in bioprocess engineering, manufacturing, and synthetic biology. Before founding Green Elephant Biotech, he worked several years in the pharmaceutical industry in vaccine manufacturing and tech transfer projects. Now at Green Elephant Biotech he is leading the development of new products and act as a linker between business development and R&D. He is passionate about building a greener future of the pharmaceutical industry and helping manufacturers and researchers to reduce their environmental impact.
Digitalisation in medicines manufacturing
- 75 mins
Accelerating CMC: the future of process development is in silico
Speaker:
Per Liden
Per Lidén joined Cytiva in 2007 and has since then held various positions in product management for lab instrumentation, bioprocess solutions, and software. At present, he leads digital product strategy for bioprocessing at Cytiva. Prior to joining Cytiva, Per was founder and CEO of a software company in the field of predictive analytics and data mining for the life science industry.
Closing summary and awards
- 15 mins
Speaker:
Steve Bates FMed Sci, OBE
Steve Bates has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.